Targeting the MOF (KAT8) protein to fight lung cancer
Targeting lysine acetyltransferase MOF/KAT8 in lung cancer
['FUNDING_R01'] · GEORGE WASHINGTON UNIVERSITY · NIH-11245777
This project looks at changing the MOF (KAT8) protein to try to slow or stop lung cancer growth in people with lung tumors.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGE WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11245777 on ClinicalTrials.gov |
What this research studies
Researchers are focusing on a protein called MOF (also KAT8) that helps switch genes on and off and may affect how lung tumors grow and spread. They will use lab experiments and mouse models to see how changing MOF activity alters cancer-related gene programs such as epithelial-to-mesenchymal transition (EMT) and inflammatory signals. The team will map which genes MOF controls in lung cancer cells and test whether loss or inhibition of MOF changes tumor development. Findings could point toward new drug targets or strategies for treating lung cancer.
Who could benefit from this research
Good fit: People with lung cancer—especially lung adenocarcinoma or tumors with molecular changes related to MOF/KAT8 pathways—would be the most relevant candidates for future therapies stemming from this work.
Not a fit: Patients without lung cancer or whose tumors do not depend on MOF-related biology are unlikely to benefit directly from these findings.
Why it matters
Potential benefit: If successful, this work could identify a new target that leads to treatments that slow tumor growth or reduce spread in some lung cancers.
How similar studies have performed: Other therapies that alter protein acetylation (like HDAC inhibitors) have shown clinical activity in some cancers, but targeting MOF/KAT8 is a newer and less-tested approach.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGE WASHINGTON UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SETO, EDWARD — GEORGE WASHINGTON UNIVERSITY
- Study coordinator: SETO, EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Prognosis, Cancer Treatment, Cancers